MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.

PloS One
Stian KnappskogPer Eystein Lønning

Abstract

The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been shown to affect cancer risk. One of these polymorphisms (SNP309T>G; rs2279744) facilitates Sp1 transcription factor binding to the promoter and is associated with increased cancer risk. In contrast, SNP285G>C (rs117039649), located 24 bp upstream of rs2279744, and in complete linkage disequilibrium with the SNP309G allele, reduces Sp1 recruitment and lowers cancer risk. Thus, fine tuning of MDM2 expression has proven to be of significant importance with respect to tumorigenesis. We assessed the potential functional effects of a third MDM2 promoter P2 polymorphism (SNP344T>A; rs1196333) located on the SNP309T allele. While in silico analyses indicated SNP344A to modulate TFAP2A, SPIB and AP1 transcription factor binding, we found no effect of SNP344 status on MDM2 expression levels. Assessing the frequency of SNP344A in healthy Caucasians (n = 2,954) and patients suffering from ovarian (n = 1,927), breast (n = 1,271), endometrial (n = 895) or prostatic cancer (n = 641), we detected no significant difference in ...Continue Reading

References

Jul 22, 1998·Nucleic Acids Research·J MomandJ Niland
Mar 7, 2003·Cancer Cell·Rossana TrottaBruno Calabretta
Dec 19, 2003·Nucleic Acids Research·Albin SandelinBoris Lenhard
Jul 11, 2006·Journal of Medical Genetics·Gareth L BondArnold J Levine
Dec 19, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Zhibin HuHongbing Shen
Jul 11, 2009·Breast Cancer Research and Treatment·Konstantinos P Economopoulos, Theodoros N Sergentanis
Mar 26, 2011·Oncotarget·Stian Knappskog, Per E Lønning
Nov 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Stian KnappskogPer E Lønning

❮ Previous
Next ❯

Citations

Oct 17, 2015·Cancer Medicine·Liv B GansmoPer Eystein Lønning
Mar 2, 2021·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Reham HelwaStian Knappskog
Apr 24, 2021·Genes & Development·Alyssa M KleinCarol Prives

❮ Previous
Next ❯

Methods Mentioned

BETA
PCRs

Software Mentioned

SPSS
Ensembl
PASW

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Stian KnappskogPer E Lønning
International Journal of Urology : Official Journal of the Japanese Urological Association
Stian Knappskog
© 2021 Meta ULC. All rights reserved